Latest Regulatory Approval News

Minerals 260 has secured an expanded mining lease and acquired additional tenements, significantly enlarging its Bullabulling Gold Project footprint and advancing towards a final investment decision in early 2027.

Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.

Foresta Group Holdings reports a doubling of its net loss to $6.8 million for FY2026 amid steady progress on its Kawerau biomass facility, highlighted by a long-term lease and key technical studies.

Berkeley Energia reported a $8.7 million net loss for FY2026 while pushing forward with its Salamanca uranium project and maiden critical minerals resource at Conchas. The company continues a $1.25 billion ICSID arbitration claim against Spain over permitting delays.

Micro-X Limited lifted revenues by 16% to $15.1 million for FY26 but posted a $9.9 million net loss, narrowing from the prior year. The company advanced key medical imaging milestones and initiated a strategic reset to sharpen commercial focus and reduce costs.

Memphasys has secured early Thai FDA approval for its Felix™ System, triggering a three-year exclusive distribution deal with IVF Envimed and prompting additional orders amid strong clinic interest.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.

Sea Forest Limited (ASX:SEA) reported a spectacular 486% surge in SeaFeed revenue for FY26, underpinned by 131,000 cattle committed, surpassing breakeven targets, and a robust $27.8 million cash buffer. The company advances its commercial footprint domestically and internationally, with carbon credit revenue set to kick off in late 2027.

Patrys has cleared a key regulatory hurdle with Human Research Ethics Committee approval for its Phase 1A clinical trial of RLS-2202, aiming to start dosing healthy volunteers this quarter.

Elevra Lithium posted a $44 million profit in FY26 after merging Sayona Mining and Piedmont Lithium, overcoming temporary mining challenges and securing full funding for the North American Lithium expansion.